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Abstract
 The term ‘male menopause’ was first used in 1944 to describe various complaints of ageing men which at 
least partially mirrored the climacteric symptoms in women. Continuous research resulted in the evolution of 
opinions about the nature of these complaints, from the clinical syndrome, diagnosed with the use of disease-
targeted questionnaires, to a well-defined clinical and biochemical syndrome. The pathophysiological causes 
– gonad ageing (with a compensatory rise in luteinizing hormone), age-related increase in serum sex hormone-
binding globulin (SHBG) levels, the role of visceral adipose tissue as a place for aromatization of androgen to 
estrogen, and lower sensitivity of testosterone receptors – have been described. However, no consensus was 
reached as far as the definition, incidence, treatment, and especially testosterone therapy, are concerned. Our re-
view presents the current standpoints, indicating the predictive role of late-onset hypogonadism (LOH) in evalu-
ating male health as well as the current literature reports on the risks and benefits of using testosterone therapy.
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Introduction
Recently, a distinct rise in the incidence of psycho-
logical disturbances has been noted among middle-
aged men [1], thus indicating an urgent need for ad-
ditional, in-depth studies to investigate that population. 
Andropausal men often have responsible professional 
functions and are at the peak of their careers but health 
and psychological problems hinder their goals and re-
sult in overall dissatisfaction, thus increasing emotional 
disturbances. The symptoms of emotional disorders 
among males at that point of their life include moodi-
ness, irritability, nervousness, depression, aggravation, 
fatigability, poor concentration, deteriorating memory, 
worse stress management and stress-related coping 
techniques, new aversion to certain activities that usu-
ally were enjoyable, or prolonged mood disorders. In 
2007, Sato et al., in their study on men from an androl-
ogy clinic, found depressive disorders in approximately 
42% of their patients, emphasizing the need to screen 
for menopause-related mood disorders among men [2]. 
Anhedonia, often described by the affected in-
dividuals as inability to experience joy, is the basic 
symptom of depression. Also, the feeling of exhaustion 
and lack of energy, resulting in reduced psychomotor 
drive, what in turn leads to a slower thinking process 
and functional cognitive impairment, is another com-
mon sign of depression. According to numerous psy-
chologists, andropause signifies the time when most 
men start to perceive their life as a whole, as a process 
rather than a  sequence of individual actions. At that 
time, men conclude that their number of days is not 
unlimited, what is often accompanied by the feeling 
of unfulfillment. Men who struggle to accept the pass-
ing of time, may find it terrifying, what consequently 
might trigger rebellion and unorthodox behavior. These 
changes herald a potential breakthrough in a man’s life, 
which leads to a more conscious life. Strong identifica-
tion with the self-perceived attractiveness and strength 
makes it challenging to accept hormonal changes and 
the related phases of life. Emotional symptoms are ac-
companied by various somatic disorders. Thus, the un-
accepted process of ageing begins.
Signs of male ageing often mirror menopausal com-
plaints in women [3]. The deteriorated general and sex-
ual condition in men was first identified in 1944 by Hel-
lers and Meyers [4] who associated it with decreased 
testosterone levels and were the first to use the term 
‘male menopause’. Heinemann and Saad [5] reported 
that sudden and excessive sweating is not gender-
dependent and the Vermeulen group even claims that 
‘climacteric symptoms’ affect both sexes and only vary 
in terms of incidence rates [6]. These assumptions vali-
dated the use of the term ‘male menopause’, or ‘an-
dropause’. Despite time and effort, emotional disorders 
resulting from decreased androgen levels are often 
treated as symptoms of depression or bipolar disease, 
and social awareness of the threatened well-being of 
men remains relatively low [7]. 
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The study by Turnover made it evident that the 
analogy between menopause and andropause may 
pertain to clinical manifestations but not the nature of 
the underlying hormonal changes. A decreased testos-
terone level – the main male hormone – is permanent 
rather than transient, and is approximately 1% per year 
[8, 9]. A recent study by Belchetz et al. [10] determined 
the total testosterone drop to be 1.4% annually. The dia-
gnosis of andropause was based on clinical symptoms 
evaluated with the use of more or less complex ques-
tionnaires that assessed subjective opinions of the pa-
tients. Wu et al. [11] generated the following results as 
far as the incidence of the major clinical symptoms is 
concerned:
•	 low libido – 91%,
•	 lack of energy – 89%,
•	 erectile dysfunction – 79%,
•	 postprandial somnolence – 77%,
•	 memory deterioration – 77%,
•	 loss of pubic hair – 70%,
•	 sadness and irritability – 68%,
•	 decreased endurance – 66%,
•	 loss of facial hair – 55%,
•	 trouble at work – 51%.
Two questionnaires for evaluating the intensity of 
the complaints have gained the largest popularity: the 
Ageing Males’ Symptoms (AMS) scale of by Claudia 
Moore et al., and the Androgen Deficiency in Ageing 
Males (ADAM) scale of Morley et al. The former assessed 
17 parameters of male well-being in three groups: psy-
chological, somatic and sexual subscales [12], whereas 
the latter, often used in its simplified version, assumed 
a definite dominance of the sexual symptoms – in fact, 
their occurrence was the decisive factor to make the 
final diagnosis [13]. 
The ADAM questionnaire in extenso is included be-
low:
 1.  Do you have a decrease in libido or sex drive? 
 2.  Do you have a lack of energy? 
 3.  Do you have a decrease in strength and/or endur-
ance? 
 4.  Have you lost height? 
 5.  Have you noticed a decrease in your enjoyment of 
life? 
 6.  Do you feel sad and/or grumpy? 
 7.  Are your erections less strong? 
 8.  Have you noticed a recent deterioration in your abil-
ity to play sports? 
 9.  Do you fall asleep after dinner?
10.  Has there been a recent deterioration in your per-
formance at work? [13].
The questionnaires were perceived as independent 
diagnostic tools and their results deemed the patient 
eligible for testosterone therapy. The management did 
not aim to compensate the deficiency but to identify 
a group of patients with possible beneficial therapeutic 
effects after testosterone administration. In practice, 
hormonal therapy, especially American one, which is 
based on testosterone administration, was in fact the 
way to prevent ageing. Even then it was obvious that 
not all men, unlike women and the post-menopausal 
estrogen drop, have testosterone deficiency. The Mas-
sachusetts Male Ageing Study (MMAS) evaluated the 
same group of men on a  long-term basis, and found 
that 21% of the investigated males aged 55-59, 26% 
aged 60-69, and 31% aged 70-86% did not meet the 
standards for testosterone levels [14]. A  further study 
revealed the results to be significantly lower if the fol-
lowing two criteria were separated: presence of the clin-
ical symptoms and testosterone levels below the norm. 
The mean age of the sample was 47.3 ± 12.5 years. 
Approximately 24% of the subjects had total testoster-
one of < 300 ng/dl, and 11% of subjects had free testos-
terone of < 5 ng/dl. Prevalence of the symptoms was as 
follows: low libido (12%), erectile dysfunction (16%), os-
teoporosis/fracture (1%), and two or more non-specific 
symptoms (20%). Low testosterone levels were associ-
ated with symptoms, but many men with low testos-
terone levels were asymptomatic (e.g. men 50+ years, 
47.6%). Crude prevalence of symptomatic androgen 
deficiency was 5.6% (95% CI: 3.6-8.6%), and was not 
significantly related to race and ethnicity. Prevalence 
was low in men < 70 years (3.1-7.0%) and increased 
markedly with age to 18.4% among 70-year-olds [15].
According to currently available studies, proper 
age-dependent reference ranges for testosterone do 
not exist and the vast majority of the published guide-
lines propose the cut-off value of 10 nmol/l [16]. The 
assumption behind testosterone therapy in men who 
presented only with clinical symptoms, without low 
testosterone levels in serum, was that, owing to a con-
siderable individual variation in serum testosterone 
concentration, a result within the normal ranges does 
not exclude a  significant decrease as compared to 
earlier results. Currently, in the era of evidence-based 
medicine, such interpretation does not stand the test 
of time.
In 2002, the International Society for Study of Age-
ing Male (ISSAM) published the first recommendations 
about diagnosis and treatment of late-onset hypogo-
nadism (LOH), updated in 2005 and 2008. They as-
sumed that the diagnosis of LOH ought to be made if 
low testosterone levels coincide with the above-men-
tioned clinical symptom. These guidelines abandon the 
practice of initiating treatment solely on the basis of 
only a positive result of the questionnaire study [17]. 
At present, Lunenfeld et al. suggested an improved 
version of these recommendations [18, 19]. Their defi-
nition of LOH, as well as interchangeably used testoster-
one deficiency syndrome (TDS), significantly expands 
the classic understanding of hypogonadism: LOH, also 
referred to as age-related TDS, is a clinical and biochem-
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ical syndrome in men with advancing age (who have 
had normal pubertal development and normal male 
secondary characteristics) associated with low testos-
terone, age-related comorbidities, and deterioration in 
the general health status. Moreover, these authors claim 
that an elevated luteinizing hormone (LH) level with to-
tal testosterone below 15 nmol/l would also suggest 
LOH. This notion is based on recently published studies, 
which in turn are the result of the European Male Age-
ing Study, indicating a marginal range of LOH incidence, 
defined as a decreased serum testosterone concentra-
tion [20]. In fact, 15 nmol/l is higher than the previously 
used population cut-off value for the total testosterone 
concentration in serum. These authors also go back to 
the notion of ‘individual norm’ of total testosterone. 
Since testosterone sensitivity may vary in different in-
dividuals, it has also been argued that the magnitude 
of the decrease in serum testosterone concentrations 
might be a  better predictor of LOH than the actual 
concentrations of total testosterone and bioavailable 
testosterone. This observation is based on the results 
of Holm et al. The Turku Male Ageing Study started in 
2000 and is still ongoing. It includes more than 15 000 
men above the age of 40 years. Current analyses indi-
cate that several major questions about the importance 
of the ageing-related decline of testosterone produc-
tion still remain unanswered. For example, a poor corre-
lation between low testosterone levels and symptoms 
of late-onset hypogonadism raises the question as to 
whether the right methods are being used to assess the 
androgen status of ageing men. Interestingly, the Turku 
data show that, unlike some previous contentions, high 
testosterone levels in ageing men are not a risk factor 
for atherosclerosis [21].
A new large study published in the "New England 
Journal of Medicine" offers other perspectives. This 
multi-center study, the European Male Ageing Study 
(EMAS), recruited 3369 men between the ages of 40 
and 79 years (mean 59.7 years), who were invited to 
undergo health assessment by questionnaire, physi-
cal and cognitive performance tests, and blood tests 
for biochemical and hormone measurements. Based 
on previous knowledge, 32 items from the EMAS ques-
tionnaires were considered as possible candidates for 
symptoms of androgen deficiency. However, only nine 
symptoms were confirmed as being related to the 
total or free testosterone levels, with significant dif-
ferences between the symptomatic and the asympto-
matic groups. These symptoms included three sexual 
manifestations (decreased frequency of morning erec-
tion, decreased frequency of sexual thoughts, and erec-
tile dysfunction), three physical symptoms (inability to 
engage in vigorous activity, e.g. running, lifting heavy 
objects, or participating in strenuous sports; inability to 
walk more than 1 km; and an inability to bend, kneel, or 
stoop), and three psychological symptoms (loss of en-
ergy, sadness [‘downheartedness’ in the questionnaire], 
and fatigue). A range of other symptoms was not linked 
with the male menopause and could be ruled out, such 
as changes in the sleeping pattern, poor concentration, 
feeling worthless, nervousness and anxiety, as well as 
difficulty in getting up from a chair. Data also enabled 
the setting of the symptom thresholds: increased proba-
bility of the three sexual symptoms and limited physical 
vigor were already detectable with the following range 
of decreased testosterone levels: 8.0-13.0 nmol/l (2.3-
3.7 ng/ml) for total testosterone, and 160-280 pmol/l 
(46-81 pg/ml) for free testosterone.
However, only the three sexual symptoms had a syn-
dromic association with decreased testosterone levels. 
An inverse relationship was observed between an in-
creasing number of sexual symptoms and a decreasing 
testosterone level. The conclusion of the study was that 
LOH actually affects only 2% of men according to their 
criteria, defined by the presence of at least three sexual 
symptoms associated with a total testosterone level of 
< 11 nmol/l (3.2 ng/ml) and a  free testosterone level 
of < 220 pmol/l (64 pg/ml) [15, 16, 21].
Ilpo Huhtaniemi terms these three clinical symp-
toms (decreased frequency of morning erection, de-
creased frequency of sexual thoughts, and erectile 
dysfunction correlated with a  serum total testoster-
one level of < 11 nmol/l) strict diagnostic criteria for 
LOH, by the analogy to a notion (well-known among 
andrologists) of ‘strict criteria’ in relation to sperm 
morphology [16]. Notably, manifestations such as the 
‘strict criteria’ many years ago tipped the scale for the 
positive result of the ADAM questionnaire. The EMAS 
supplied the basis for earlier historical, empirical ob-
servations. Even such strict criteria cannot be per-
ceived as fully representative. Endocrine foundation 
of the erectile dysfunction is not only hypoandrogen-
ism. Evaluation of thyroid stimulating hormone (TSH), 
LH, and prolactin might be performed together with 
testosterone assessment. There is still no definite 
evidence of the role of estradiol, dihydrotestosterone 
(DHT), dehydroepiandrosterone (DHEA), dehydroepi-
androsterone sulfate (DHEA-S), cortisol, growth hor-
mone (GH), or insulin-like growth factor 1 (IGF-1) in 
erectile dysfunction (ED) [22].
The pathomechanism of LOH includes several pos-
sible paths resulting in decreased testosterone levels 
[23]:
•	 a decline in the function of Leydig cells and the pitui-
tary-hypothalamic axis,
•	 an increase in the levels of sex hormone-binding 
globulin (SHBG), which occurs with advancing age 
and consequently leads to less free testosterone,
•	 the presence of visceral fat. 
Visceral adipose tissue is the most metabolically ac-
tive adipose tissue in human body and drains through 
the portal vein to the liver, the consequences of which 
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lead to peripheral hyperinsulinemia and systemic in-
sulin resistance. The underlying mechanisms responsi-
ble for the reduced testosterone levels in obese men 
are unknown. Possible mechanisms include a  form of 
hypo gonadotrophic hypogonadism, hyperoestrogenemia 
from peripheral conversion of testosterone which leads 
to a further reduction in serum and tissue testosterone 
concentrations, increased deposition of abdominal fat, 
and progressive hypogonadism [24]. Serum testoster-
one in a man with body mass index (BMI) > 30 kg/m2 
is, on average, 30% lower than that of a man with BMI 
< 25 kg/m2, at any age, which is more than a  purely 
age-dependent decrease between 40 and 80 years. Cu-
riously, the decrease in testosterone secretion associ-
ated with obesity and chronic illness is not associated 
with a  compensatory increase in gonadotropin levels, 
thus indicating a secondary central mechanism for the 
disturbance [20].
Visceral tissue also produces inflammatory cyto-
kines and promotes endothelial dysfunction and vas-
cular diseases [25].
A possible decline in the sensitivity of testosterone 
receptors, especially those in the central nervous sys-
tem (CNS), may explain both the decrease in sexual de-
sire in the ageing male and the need for a larger dose of 
testosterone when treating hypogonadism [23].
The above-mentioned phenomena may constitute 
the foundation for the debate, and the first two patho-
mechanisms are quite commonly accepted – gonad 
ageing compensated by increased pituitary activity 
stimulation via LH. The mechanism is as close as pos-
sible to menopause (low estrogens, high gonadotropin 
levels), despite the absence of the inability to produce 
estrogens, which is characteristic for climacteric wom-
en, in men gonad ageing occurs but its function is pre-
served, and additionally higher bonding to SHBG takes 
place, what results in lower androgenization. 
Androgen aromatization in the visceral adipose tis-
sue in obese men seems to be analogous to that in their 
sex counterparts. Also, the theory of lower receptor 
sensitivity for androgens is most promising. It allows to 
explain the coincidence of normal testosterone concen-
trations and clinical symptoms typical of andropause. 
Regardless, such pathomechanism does not account for 
the beneficial effect of androgen administration, which 
should have only limited value.
The model suggested by Wylie and Froggat allows 
to bring together the low rates of men with ‘real’ LOH, 
i.e. defined according to the EAMS and earlier MMAS 
guidelines [15], with the common belief of clinicians 
that hypoandrogenism-related problems of ageing men 
remain underestimated. 
A cross-sectional cohort study identified symptom 
specific threshold levels with androgen-induced preva-
lence of loss of libido or vigor increased when testos-
terone concentrations were below 15 nmol/l, whereas 
depression and diabetes mellitus type 2 (also in non-
obese men) were significantly higher in men with tes-
tosterone concentrations of < 10 nmol/l [26]. The prob-
lem of the cut-off value for serum testosterone remains 
to be resolved. In their latest recommendations, Lunen-
feld et al. mention the value of 15 nmol/l [18, 19].
In summary, there is general agreement that serum 
total testosterone levels of 8 nmol/l (231 ng/dl) or free 
testosterone of 5180 pmol/l (52 pg/ml) require substitu-
tion. A trial of testosterone is indicated for patients with 
total testosterone levels of between 8 and 12 nmol/l, 
if there is evidence of clinical symptoms, and the free 
testosterone level is less than 225 pmol/l [27].
The fact that every laboratory has its own set of 
norms, whose literature background remains unknown, 
and that virtually all of them establish the lower norm 
at the level of < 300 ng/ml, thus making it impossible to 
relate to the literature, constitutes an additional prob-
lem for Polish clinicians. Regardless, large population 
studies like MMAS and EAMS also used a  lower cut-
off value, and additionally the values were different in 
these two cases. 
Late-onset hypogonadism treatment
As far as LOH treatment is concerned, it is impor-
tant to emphasize that, according to the EMAS data, it 
is possible to state almost categorically that if a man 
does not have sexual symptoms he does not have LOH 
[20]. On the other hand, a significant number of men 
seeking medical help are reluctant to discuss the topic 
of sexual dysfunctions with their family doctor. There-
fore, a medical interview with a low testosterone level 
patient ought to be very detailed and, as such, may pre-
sent a challenge for the physician. It seems that, as in 
case of women and menopause, the first-line treatment 
consists in lifestyle changes. 
Recent EMAS data show that weight gain or loss 
have a clear inverse correlation with circulating testos-
terone and vice versa. Testosterone treatment has im-
portant effects on body composition, resulting in a sig-
nificant increase in lean body mass, and a significant 
decrease in fat mass without a change in body weight 
[28, 29]. Moreover, the risk of experiencing adverse 
effects associated with testosterone treatment was 
reported to increase in obese subjects [30], therefore 
weight loss using testosterone therapy should be con-
ducted with care and attention. Similar caution should 
be advised when suggesting a program of intense phys-
ical exercises as it may have a detrimental effect on the 
lipid profile in men, just like testosterone therapy [31].
Because LOH symptoms are similar to those of 
hypogonadism in young men, testosterone replace-
ment therapy has become a popular treatment option. 
Improvement of symptoms should be assessed after 
a few months of treatment. If no benefits are reported 
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by the patient, treatment should be terminated and 
other causes of symptoms should be investigated. If 
the treatment is effective, the patients should be moni-
tored with regular checking of their hematocrit, hemo-
globin and prostate specific antigen (PSA) levels and 
by doing digital rectal examination every 3-6 months 
[32]. Since the possible development of an adverse 
event during treatment, especially elevated hematocrit 
or prostate carcinoma, requires rapid discontinuation 
of testosterone substitution, short-acting preparations 
may be preferred over long-acting depot preparations 
in the initial treatment of patients with LOH [33].
Currently, absolute contraindications to testoster-
one therapy include prostate and breast cancer. Relative 
contraindications are serum PSA level of > 4 ng/ml (or 
3 ng/ml in men with an increased risk of prostate cancer, 
hematocrit > 50%, severe lower urinary tract symptoms 
caused by benign prostatic hypertrophy (as defined by 
an International Prostate Symptom Score [IPSS] high-
er than 19), untreated or poorly controlled congestive 
heart failure, and untreated sleep apnea [34]. A review 
of the literature shows that testosterone treatments 
have not been proven to be beneficial with respect to 
cardiovascular disease, nor have they definitely shown 
specific adverse cardiovascular effects [35].
We still lack randomized, placebo-controlled studies 
on testosterone replacement in men aged ≥ 60 years. 
The existing trials have low numbers of subjects and 
are often of insufficient duration [36]. At the moment, 
a controlled-placebo study in a group of 800 men is be-
ing carried out in the USA, and the results are antici-
pated in 2015. 
Currently, the testosterone therapy remains the top-
ic of a much heated debate and the arguments are of-
ten radical, e.g. Handelsmann is of the opinion that the 
reasons for testosterone therapy are often non-medical, 
and that the marketing of testosterone treatments has 
been aggressive and effective, especially in the United 
States, where the sales volume of testosterone prepa-
rations keeps rising, doubling between 2005 and 2010 
[37]. Kaufman offers a more measured standpoint, em-
phasizing that the finding of a  severe LOH should be 
taken by clinicians as a warning of a potentially high-
risk health status of their patient and should prompt 
them to take appropriate actions, which in the present 
state of the art should not include testosterone treat-
ment [38]. In Poland, such aggressive marketing is not 
noticeable, the majority of preparations are not even 
present on the market, and testosterone use in patients 
with diagnosed TDS is, unfortunately, marginal. Intro-
duction of the selective androgen receptor modulators 
(SARMs) to clinical practice might be of importance as 
it would allow to exclude the detrimental effect on the 
prostate and the cardiovascular system, with simultane-
ous benefits for the sexual functions, mood, and osteo-
porotic prevention [39]. 
Apart from the direct impact of LOH on the quality 
of life of the ageing males, its predictive value is increas-
ingly debated: subjects with compensated or overt hypo-
gonadism had an increased predicted risk of cardiovas-
cular events (assessed by Progetto Cuore risk algorithm), 
as compared to eugonadal individuals. Accordingly, mor-
tality related to major adverse cardiovascular events 
(MACEs), but not MACE incidence, was significantly 
higher in subjects with both compensated and overt 
hypogonadism as compared to eugonadal subjects. 
The possibility that subclinical hypogonadism could be 
a normal response of the hypothalamus-pituitary-testis 
axis to somatic illness should be considered [40].
In conclusion, in light of new population-based 
studies, the existence of the clinical and biochemical 
syndrome known as LOH has been confirmed, but its 
incidence appears to be notably lower than originally 
estimated. Regardless, a  group of authors who are in 
direct opposition remains active. Research and recom-
mendations of Lunnefeld postulate to initiate therapy 
even at a testosterone level of 15 nmol/l and presence 
of clinical manifestations. The general consensus is 
that LOH constitutes a  predictive value for the entire 
well-being of a  man and may identify him as a  high-
risk candidate for numerous diseases. However, there is 
no consensus on the risk-benefit index in testosterone 
therapy. A large interventional study, currently conduct-
ed in the USA and scheduled to end in 2015, offers hope 
to break the impasse.
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